Kyowa Kirin Co., Ltd. (TYO:4151)

Market Cap	1.25T +8.6%
Revenue (ttm)	510.57B +3.2%
Net Income	72.91B +41.8%
EPS	139.27 +42.6%
Shares Out	523.49M
PE Ratio	17.15
Forward PE	15.01
Dividend	70.00 (2.92%)
Ex-Dividend Date	Jun 29, 2026

Volume	538,200
Average Volume	1,394,850
Open	2,378.50
Previous Close	2,388.00
Day's Range	2,372.00 - 2,432.00
52-Week Range	2,109.00 - 2,912.00
Beta	0.10
RSI	47.89
Earnings Date	May 7, 2026

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodular...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1949
• Employees: 5,161
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4151

Financial Performance

In 2025, Kyowa Kirin's revenue was 496.83 billion, an increase of 0.26% compared to the previous year's 495.56 billion. Earnings were 67.04 billion, an increase of 11.98%.